74 results
Keyword Sitagliptin Remove keyword
-
List item
Sitagliptin product-specific bioequivalence guidance
Bioequivalence, generics, sitagliptin … Sitagliptin product-specific bioequivalence …
-
List item
Product-specific bioequivalence guidance
Last updated: 06/10/2015product-specific bioequivalence guidance Sitagliptin product-specific bioequivalence …
-
List item
Article 5(3) opinions
Last updated: 26/09/2019 -
List item
PRAC recommendations on safety signals
Last updated: 30/09/2019 -
List item
PRAC: Agendas, minutes and highlights
Last updated: 14/06/2019 -
List item
Medicines under evaluation
Last updated: 18/02/2019 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 March 2018
European Medicines Agency, London, UK, from 05/03/2018 to 08/03/2018, Last updated: 05/03/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 March 2018
European Medicines Agency, London, UK, from 19/03/2018 to 22/03/2018, Last updated: 31/05/2018 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 28/01/2019 -
List item
PRAC recommendations on safety signals: monthly overviews: Archive
-
List item
Paediatric Committee (PDCO): 20-22 May 2015
European Medicines Agency, London, UK, from 20/05/2015 to 22/05/2015, Last updated: 20/05/2015 -
List item
Annual reports and work programmes
Last updated: 03/05/2019 -
List item
Paediatric Committee (PDCO): 24-26 February 2016
European Medicines Agency, London, UK, from 24/02/2016 to 26/02/2016, Last updated: 24/02/2016 -
List item
PRAC: meeting archive 2012-2013
-
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 April 2015
European Medicines Agency, London, UK, from 07/04/2015 to 10/04/2015, Last updated: 20/05/201514 4.1.3. Sitagliptin - JANUVIA (CAP), RISTABEN … TESAVEL (CAP), XELEVIA (CAP) Sitagliptin, metformin hydrochloride … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 April 2018
European Medicines Agency, London, UK, from 09/04/2018 to 12/04/2018, Last updated: 13/03/2014 -
List item
Paediatric Committee (PDCO): 30 March – 1 April 2016
European Medicines Agency, London, UK, from 30/03/2016 to 01/04/2016, Last updated: 30/06/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 September 2018
European Medicines Agency, London, UK, from 03/09/2018 to 06/09/2018, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 May 2014
European Medicines Agency, London, UK, from 05/05/2014 to 08/05/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 23-26 October 2017
European Medicines Agency, London, UK, from 23/10/2017 to 26/10/2017, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 July 2013
European Medicines Agency, London, UK, from 08/07/2013 to 11/07/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 October 2015
European Medicines Agency, London, UK, from 05/10/2015 to 08/10/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 December 2013
European Medicines Agency, London, UK, from 02/12/2013 to 05/12/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 February 2013
European Medicines Agency, London, UK, from 04/02/2013 to 07/02/2013, Last updated: 02/06/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-5 September 2012
European Medicines Agency, London, UK, from 03/09/2012 to 05/09/2012, Last updated: 02/06/2012to be appointed 4.1.7. Sitagliptin - JANUVIA, RISTABEN, TESAVEL …